Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
| Revenue (TTM) | $796.33M |
| Gross Profit (TTM) | $710.08M |
| EBITDA | $425.05M |
| Operating Margin | 16.00% |
| Return on Equity | 27.40% |
| Return on Assets | 7.60% |
| Revenue/Share (TTM) | $25.06 |
| Book Value | $9.64 |
| Price-to-Book | 3.53 |
| Price-to-Sales (TTM) | 1.39 |
| EV/Revenue | 1.871 |
| EV/EBITDA | 3.63 |
| Quarterly Earnings Growth (YoY) | -46.60% |
| Quarterly Revenue Growth (YoY) | 8.90% |
| Shares Outstanding | $32.43M |
| Float | $32.05M |
| % Insiders | 1.16% |
| % Institutions | 127.60% |
Volatility is currently contracting